Torgauten HM, Onyango TB, Ljostveit S, Hallin EI, Serkland TT, Skrede S, Langeland N, Cox RJ, Wergeland S, Myhr K-M, Torkildsen Ø. Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2024. https://doi.org/10.1016/j.msard.2024.105770. https://www.sciencedirect.com/science/article/pii/S221103482400347X
Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium. Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1-AGED Part B). Int J Infect Dis. 2024 Jul 9:107161. doi: 10.1016/j.ijid.2024.107161. Epub ahead of print. PMID: 38992789. https://pubmed.ncbi.nlm.nih.gov/38992789/
Cox RJ, Pathirana R. Unravelling influenza correlates of protection: lessons from human A/H1N1 Challenge. mBio. 2024 May 8;15(5):e0006424. doi: 10.1128/mbio.00064-24. PMID: 38546212. https://journals.asm.org/doi/10.1128/mbio.00064-24
Salmanton-García J, Wipfler P, Leckler J, Nauclér P, Mallon PW, Bruijning-Verhagen PCJL, Schmitt HJ, Bethe U, Olesen OF, Stewart FA, Albus K, Cornely OA; VACCELERATE Consortium. Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics. Travel Med Infect Dis. 2024 Jan-Feb;57:102676. doi: 10.1016/j.tmaid.2023.102676.. PMID: 38061408. https://pubmed.ncbi.nlm.nih.gov/38061408/
Iversen A, Blomberg B, Haug K, Kittang B, Özgümüs T, Cox RJ, Langeland N. Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway. Front Public Health. 2024 Mar 5;12:1320059. doi: 10.3389/fpubh.2024.1320059. PMID: 38504678. https://pubmed.ncbi.nlm.nih.gov/38504678/
Zhou F, Vahokoski J; Bergen COVID-19 Research Group; Langeland N, Cox RJ. Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. NPJ Vaccines. 2024 Feb 20;9(1):37. doi: 10.1038/s41541-024-00817-z. PMID: 38378953. https://pubmed.ncbi.nlm.nih.gov/38378953/
Corti N, Chiu C, Cox RJ, Demont C, Devaster J-M, Engelhardt O, Gorringe A, Hassan K, Hoefnagel M, Kamerling I, Krut O, Lane C, Liebers R, Luke C, Van Molle W, Morel S, Neels P, Roestenberg M, Rubbrecht M, Klaas Smits W, Stoughton D, Talaat K, Vehreschild M J.G.T., Wildfire A, Meln I, Olesen OF. Regulatory workshop on challenge strain development and GMP manufacture – A stakeholder meeting report, Biologicals. 2024. 101746,ISSN 1045-1056. https://doi.org/10.1016/j.biologicals.2024.101746. https://www.sciencedirect.com/science/article/pii/S1045105624000034
2024
2023
Hansen L, Brokstad KA, Bansal A, Zhou F, Bredholt G, Bredholt Onyango T, Sandnes HH, Elyanow R, Madsen A, Trieu MC, Sævik M, Søyland H, Olofsson JS, Vahokoski J, Ertesvåg NU, Fjelltveit EB, Shafiani S, Tøndel C, Chapman H, Kaplan I, Mohn KGI, Langeland N, Cox RJ. Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine X, 2023;13,100262. https://pubmed.ncbi.nlm.nih.gov/36643855/
Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity. 2023 Aug 8;56(8):1927-1938.e8. doi: 10.1016/j.immuni.2023.07.004. Epub 2023 Jul 27. PMID: 37506693. https://pubmed.ncbi.nlm.nih.gov/37506693/
Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías-Iniesta J, Davis RJ, Barta I, Azzini AM, Askling HH, Argyropoulos CD, Álvarez-Barco E, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Flisiak R, Husa P, Jancoriene L, Koscalova A, Launay O, Lundgren J, Mallon P, Marques L, Nauclér P, Ochando J, Pana ZD, Tacconelli E, Tóth K, Trelle S, van Damme P, Zaoutis TE, Zeitlinger M, Albus K, Stewart FA, Hofstraat SHI, Bruijning-Verhagen P, Cornely OA; VACCELERATE Consortium. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Vaccine. 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006. Epub 2023 May 18. PMID: 37210309. https://pubmed.ncbi.nlm.nih.gov/37210309/
Argyropoulos CD, Leckler J, Salmanton-García J, Constantinou M, Alexandrou A, Themistocleous S, Noula E, Shiamakkides G, Nearchou A, Stewart FA, Albus K, Koniordou M, Kopsidas I, Spivak O, Hellemans M, Hendrickx G, Davis RJ, Azzini AM, Simon PV, Carcas-Sansuan AJ, Askling HH, Vene S, Prellezo JB, Álvarez-Barco E, Macken AJ, Di Marzo R, Luís C, Olesen OF, Frias Iniesta JA, Barta I, Tóth K, Akova M, Bonten MMJ, Cohen-Kandli M, Cox RJ, Součková L, Husa P, Jancoriene L, Launay O, Lundgren J, Mallon P, Armeftis C, Marques L, Naucler P, Ochando J, Tacconelli E, van Damme P, Zaoutis T, Hofstraat S, Bruijning-Verhagen P, Zeitlinger M, Cornely OA, Pana ZD. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit. JMIR Public Health Surveill. 2023 Apr 3;9:e44491. doi: 10.2196/44491. PMID: 36878478. https://pubmed.ncbi.nlm.nih.gov/36878478/
Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, Elyanow R, Kaplan IM, Tøndel C, Mohn KGI, Özgümüş T, Cox RJ, Langeland N; Bergen COVID-19 Research Group. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clin Infect Dis. 2023 Feb 8;76(3):e60-e70. doi: 10.1093/cid/ciac655. PMID: 35959897. https://pubmed.ncbi.nlm.nih.gov/35959897/
Waldock J, Remarque EJ, Zheng L, Ho S, Hoschler K, Neumann B, Sediri-Schön H, Trombetta CM, Montomoli E, Marchi S, Lapini G, Zhou F, Lartey SL, Cox RJ, Facchini M, Castrucci MR, Friel D, Ollinger T, Caillet C, Music N, Palladino G, Engelhardt OG; FLUCOP consortium. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study. Front Immunol. 2023 Apr 18;14:1155552. doi: 10.3389/fimmu.2023.1155552. eCollection 2023. PMID: 37143658. https://pubmed.ncbi.nlm.nih.gov/37143658/
Ertesvåg NU, Iversen A, Blomberg B, Özgümüş T, Rijal P, Fjelltveit EB, Cox RJ, Langeland N; Bergen COVID-19 research group. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine. 2023 Jun;92:104599. doi: 10.1016/j.ebiom.2023.104599. Epub 2023 May 5. PMID: 37149931. https://pubmed.ncbi.nlm.nih.gov/37149931/
Bansal A, Trieu MC, Mohn KGI, Madsen A, Olofsson JS, Sandnes HH, Sævik M, Søyland H, Hansen L, Onyango TB, Tøndel C, Brokstad KA; Bergen COVID-19 research group; Syre H, Riis ÅG, Langeland N, Cox RJ. Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Front Public Health. 2023 Jul 21;11:1164326. doi: 10.3389/fpubh.2023.1164326. eCollection 2023. PMID: 37546332. https://pubmed.ncbi.nlm.nih.gov/37546332/
Meskell P, Biesty LM, Dowling M, Roche K, Meehan E, Glenton C, Devane D, Shepperd S, Booth A, Cox R, Chan XHS, Houghton C. Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2023 Sep 1;9(9):MR000065. doi: 10.1002/14651858.MR000065.pub2. PMID: 37655964 Review. https://pubmed.ncbi.nlm.nih.gov/37655964/
Onyango TB, Zhou F, Bredholt G, Brokstad KA, Lartey S, Mohn KG, Özgümüs T, Kittang BR, Linchausen DW, Shafiani S, Elyanow R, Blomberg B, Langeland N, Cox RJ; Bergen COVID-19 Research Group. SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Front Immunol. 2023 Nov 2;14:1287388. doi: 10.3389/fimmu.2023.1287388. eCollection 2023. PMID: 38022529. https://pubmed.ncbi.nlm.nih.gov/38022529/
Wolff ASB, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES. Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 2023 Jul 21;26(7):107084. doi: 10.1016/j.isci.2023.107084. Epub 2023 Jun 9. PMID: 37346050. https://pubmed.ncbi.nlm.nih.gov/37346050/
Mohn KG, Bredholt G, Onyango TB, Brokstad KA, Zhou F, Holter JC, Tonby K, Dyrhol-Riise AM, Cox RJ; Bergen COVID-19 Research Group; Norwegian SARS-CoV-2 Study Group. SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity. J Infect. 2023 Oct;87(4):346-349. doi: 10.1016/j.jinf.2023.05.023. Epub 2023 Jun 8. PMID: 37295510. https://pubmed.ncbi.nlm.nih.gov/37295510/
Kenny G, O'Reilly S, Wrigley Kelly N, Negi R, Gaillard C, Alalwan D, Saini G, Alrawahneh T, Francois N, Angeliadis M, Garcia Leon AA, Tinago W, Feeney ER, Cotter AG, de Barra E, Yousif O, Horgan M, Doran P, Stemler J, Koehler P, Cox RJ, O'Shea D, Olesen OF, Landay A, Hogan AE, Lelievre JD, Gautier V, Cornely OA, Mallon PWG; All Ireland Infectious Diseases Cohort Study; VACCELERATE Consortium EU-COVAT-1-AGED Part A Study Group. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nat Commun. 2023 Nov 2;14(1):7015. doi: 10.1038/s41467-023-42717-1. PMID: 37919289. https://pubmed.ncbi.nlm.nih.gov/37919289/
Beukema M, Gong S, Al-Jaawni K, de Vries-Idema JJ, Krammer F, Zhou F, Cox RJ, Huckriede A. Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice. Front Immunol. 2023 Oct 5;14:1249902. doi: 10.3389/fimmu.2023.1249902. eCollection 2023. PMID: 37869002. https://pubmed.ncbi.nlm.nih.gov/37869002/
Waerlop G, Leroux-Roels G, Pagnon A, Begue S, Salaun B, Janssens M, Medaglini D, Pettini E, Montomoli E, Gianchecchi E, Lambe T, Godfrey L, Bull M, Bellamy D, Amdam H, Bredholt G, Cox RJ, Clement F. Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols. J Immunol Methods. 2023 Dec;523:113584. doi: 10.1016/j.jim.2023.113584. Epub 2023 Oct 31. PMID: 37918618. https://pubmed.ncbi.nlm.nih.gov/37918618/
Waldock J, Weiss CD, Wang W, Levine MZ, Jefferson SN, Ho S, Hoschler K, Londt BZ, Masat E, Carolan L, Sánchez-Ovando S, Fox A, Watanabe S, Akimoto M, Sato A, Kishida N, Buys A, Maake L, Fourie C, Caillet C, Raynaud S, Webby RJ, DeBeauchamp J, Cox RJ, Lartey SL, Trombetta CM, Marchi S, Montomoli E, Sanz-Muñoz I, Eiros JM, Sánchez-Martínez J, Duijsings D, Engelhardt OG. An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study. Front Immunol. 2023 Feb 28;14:1129765. doi: 10.3389/fimmu.2023.1129765. eCollection 2023. PMID: 36926342. https://pubmed.ncbi.nlm.nih.gov/36926342/
Poulimeneas D, Koniordou M, Kousi D, Merakou C, Kopsidas I, Tsopela GC, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Constantinou M, Alexandrou A, Noula E, Nearchou A, Salmanton-García J, Stewart FA, Heringer S, Albus K, Álvarez-Barco E, Macken A, Di Marzo R, Luis C, Valle-Simón P, Askling HH, Hellemans M, Spivak O, Davis RJ, Azzini AM, Barta I, Součková L, Jancoriene L, Akova M, Mallon PWG, Olesen OF, Frias-Iniesta J, van Damme P, Tóth K, Cohen-Kandli M, Cox RJ, Husa P, Nauclér P, Marques L, Ochando J, Tacconelli E, Zeitlinger M, Cornely OA, Pana ZD, Zaoutis TE; VACCELERATE Consortium. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium. Vaccines (Basel). 2023 Nov 29;11(12):1784. doi: 10.3390/vaccines11121784. PMID: 38140188. https://pubmed.ncbi.nlm.nih.gov/38140188/
Bansal A. Critique of a Study on Breast Ultrasound as an Adjunct to Breast Tomosynthesis for Breast Cancer Screening and Diagnosis. Ultrasound Med. Biol. 2023. S0301-5629(23)00373-3. 5. doi: https://doi.org/10.1016/j.ultrasmedbio.2023.11.015. https://www.umbjournal.org/article/S0301-5629(23)00373-3/fulltext
Bansal A. From rejection to the Nobel Prize: Karikó and Weissman’s pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology. 11. Front Immunol. 2023;14. doi: 12. https://doi.org/10.3389/fimmu.2023.1306025. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1306025/full
Amdam H, Norheim OF, Solberg CT, Littman J. Can Geographically Targeted Vaccinations Be Ethically Justified? The Case of Norway During the COVID-19 Pandemic. Public Health Ethics. 2023, 16 (2), 139-151. 10.1093/phe/phad011. https://bora.uib.no/bora-xmlui/handle/11250/3093104
Rim S, Sakkestad ST, Zhou F, Gullaksen SE, Skavland J, Chauhan SK, Steinsland H, Hanevik K. Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection. Eur. J. Immunol.. 2023. 53: 2250254. https://doi.org/10.1002/eji.202250254. https://onlinelibrary.wiley.com/doi/10.1002/eji.202250254
2023
2022
Fjelltveit EB, Blomberg B, Kuwelker K, Zhou F, Onyango TB, Brokstad KA, Elyanow R, Kaplan IM, Tøndel C, Mohn KG-I, Özgümüş T, Cox RJ, Langeland N, Bergen COVID-19 Research Group, Symptom burden and immune dynamics 6 to 18 months following mild SARS-CoV-2 infection -a case-control study, Clinical Infectious Diseases, 2022;, ciac655, https://doi.org/10.1093/cid/ciac655; https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac655/6663664
Ertesvåg NU, Cox RJ, Lartey SL. et al. Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. npj Vaccines 7, 67 (2022). https://doi.org/10.1038/s41541-022-00490-0; https://www.nature.com/articles/s41541-022-00490-0
Ertesvåg NU, Sakkestad ST, Zhou F, Hoff I, Kristiansen T, Jonassen TM, Follesø E, Brokstad KA, Dyrhovden R, Mohn KG-I. Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. Viruses 2022, 14, 1757. https://doi.org/ 10.3390/v14081757; https://www.mdpi.com/1999-4915/14/8/1757
McKimm-Breschkin JL, Hay AJ, Cao B, Cox RJ, Dunning J, Moen AC, Olson D, Pizzorno A, Hayden FG. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022 Jan;197:105227. doi: 10.1016/j.antiviral.2021.105227; https://pubmed.ncbi.nlm.nih.gov/34933044/
Fjelltveit EB, Cox RJ, Kittang BR, Blomberg B, Buanes EA; Group Bergen COVID-19 Research, Langeland N, Mohn KG. Lower antibiotic prescription rates in hospitalized COVID-19 patients than influenza patients, a prospective study. Infect Dis (Lond). 2022 Feb;54(2):79-89; https://pubmed.ncbi.nlm.nih.gov/34525895/
Mohn KG-I, Bredholt G, Zhou F, Madsen A, Onyango TB, Fjelltveit EB, et al. (2022) Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLoS ONE 17(2): e0261979. https://doi.org/10.1371/journal.pone.0261979; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261979
Ertesvåg NU, Xiao J, Zhou F, et al. (2022) A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Commun Med 2, 36 . https://doi.org/10.1038/s43856-022-00091-x; https://www.nature.com/articles/s43856-022-00091-x
Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K, Thomassen KS, Kro GB, Cox RJ, Zhou F, Langeland N, Aukrust P, Melum E, Åvitsland TL, Wiencke K, Holter JC, Munthe LA, Grødeland G, Andersen JT, Vaage JT, Lund-Johansen F. Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. NPJ Vaccines. 2023 Jan 25;8(1):4. doi: 10.1038/s41541-023-00600-6. PMID: 36697432. https://pubmed.ncbi.nlm.nih.gov/36697432/
2022
2021
Amdam H, Madsen A, Zhou F, Bansal A, Trieu MC, Cox RJ. Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014). Front Immunol. 2021 Dec 6;12:748281. doi: 10.3389/fimmu.2021.748281; https://www.frontiersin.org/articles/10.3389/fimmu.2021.748281/full
Bansal A, Trieu M-C, Mohn KGI, Cox RJ. Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Frontiers in Immunology. 2021;12(3926); https://www.frontiersin.org/articles/10.3389/fimmu.2021.744774/full
Blomberg B, Mohn KG, Brokstad KA, et al. Cox RJ, Langeland N. Long COVID in a prospective cohort of home-isolated patients. Nat Med; https://pubmed.ncbi.nlm.nih.gov/34163090/
Trieu MC, Bansal A, Madsen A, et al. Cox RJ . SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. J Infect Dis. 2021;223(4):589-599; https://pubmed.ncbi.nlm.nih.gov/33247924/
Kuwelker K, Zhou F, Blomberg B, et al. Cox RJ, Langeland N Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. The Lancet Regional Health – Europe. 2021;3; https://pubmed.ncbi.nlm.nih.gov/33871470/
Cox RJ, Brokstad KA, Krammer F, Langeland N, Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Lancet Infect Dis. 2021;21(2):168; https://pubmed.ncbi.nlm.nih.gov/32553187/
Waldock J, Zheng L, Remarque EJ, et al. Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study. 2021;6(4):e0056721; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530177/
Paramsothy A, Lartey Jalloh S, Davies RA, Guttormsen AB, Cox RJ, Mohn KG. Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scand J Immunol. 2021;94(2):e13045; https://pubmed.ncbi.nlm.nih.gov/33891354/
Madsen A, Jul-Larsen A, Trieu MC, Krammer F, Cox RJ. Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response. NPJ Vaccines. 2021;6(1):45; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016826/
Zhou F, Hansen L, Pedersen G, Grødeland G, Cox R. Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. Front. Immunol. 2021. 12:747774. doi: 10.3389/fimmu.2021.747774. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.747774/full
2021
2020
Venkatesan S, Myles PR, Bolton KJ, et al. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J Infect Dis. 2020;221(3):356-366; https://pubmed.ncbi.nlm.nih.gov/31314899/
Riese P, Trittel S, Pathirana RD, Klawonn F, Cox RJ, Guzman CA. Responsiveness to Influenza Vaccination Correlates with NKG2C-Expression on NK Cells. Vaccines (Basel). 2020;8(2); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349951/
Pollard AJ, Sauerwein R, Baay M, Neels P, speakers HCT, session c. Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report. 2020;66:41-52; https://pubmed.ncbi.nlm.nih.gov/32505512/
Mohn KG, Brokstad KA, Islam S, et al. Cox RJ. Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. J Infect Dis. 2020;221(9):1528-1537; https://academic.oup.com/jid/article/221/9/1528/5817020
Madsen A, Dai YN, McMahon M, et al. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. 2020;53(4):852-863 e857; https://pubmed.ncbi.nlm.nih.gov/32976769/
Madsen A, Cox RJ. Prospects and Challenges in the Development of Universal Influenza Vaccines. Vaccines (Basel). 2020;8(3); https://www.mdpi.com/2076-393X/8/3/361
Lartey S, Zhou F, Brokstad KA, et al. Cox RJ. Live-Attenuated Influenza Vaccine Induces Tonsillar Follicular T Helper Cell Responses That Correlate With Antibody Induction. J Infect Dis. 2020;221(1):21-32; https://pubmed.ncbi.nlm.nih.gov/31250024/
Krammer F, Weir JP, Engelhardt O, Katz JM, Cox RJ. Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza Other Respir Viruses. 2020;14(2):237-243; https://pubmed.ncbi.nlm.nih.gov/31837101/
Fjelltveit EB, Cox RJ, Ostensjo J, et al. Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. J Infect Dis, https://pubmed.ncbi.nlm.nih.gov/33151320/
Bjork A, Thorlacius GE, Mofors J, et al. Viral antigens elicit augmented immune responses in primary Sjogren's syndrome. Rheumatology (Oxford). 2020;59(7):1651-1661; https://pubmed.ncbi.nlm.nih.gov/31665501/
2020
2019
Tunheim G, Laake I, Robertson AH, et al. Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness. Influenza Other Respir Viruses. 2019;13(2):191-200; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379636/
Trieu MC, Jul-Larsen A, Saevik M, et al. Cox RJ. Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study. Clin Infect Dis. 2019;68(3):382-392; https://pubmed.ncbi.nlm.nih.gov/29893797/
Madsen A, Azimi L, Tete S, et al. Cox RJ. No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination. Vaccine X. 2019;2:100029; https://pubmed.ncbi.nlm.nih.gov/31384744/
Islam S, Zhou F, Lartey S, et al. Cox RJ. Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination. Scand J Immunol. 2019;90(4):e12801; https://pubmed.ncbi.nlm.nih.gov/31269273/
Bodin J, Mihret A, Holm-Hansen C, et al. Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. 2019;11(3); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471093/
Mohn KGI, Brokstad KA, Islam S, Oftung F, Tøndel C, Aarstad HJ, Cox RJ. Early induction of cross-reactive CD8+ T-cell responses in tonsils after LAIV vaccination in children J Infect Dis. 2019;in press. https://pubmed.ncbi.nlm.nih.gov/32255493/
Björk A, Thorlacius GE, Mofors J, Richardsdotter Andersson E, Ivanchenko M, Tingström J, James T, Brokstad KA, Cox RJ, Jonsson R, Kvarnström M, Wahren-Herlenius M. Viral antigens elicit augmented immune responses in primary Sjögren's syndrome. Rheumatology (Oxford). 2019 Oct 30. pii: kez509. doi: 10.1093/rheumatology/kez509. https://pubmed.ncbi.nlm.nih.gov/31665501/
Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J Infect Dis. 2019 Jul 17. pii: jiz152. doi: 10.1093/infdis/jiz152. https://pubmed.ncbi.nlm.nih.gov/31314899/
Lartey S, Zhou F, Brokstad KA, Mohn KGI, Slettevoll SA, Pathirana RD, Cox RJ. Live attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. JID 2019 in press. DOI: 10.1093/infdis/jiz321. https://pubmed.ncbi.nlm.nih.gov/31250024/
Lanevski A, Zusinaite E, Shtaida N, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Dumpis U, Vitkauskiene A, Stašaitis K, Öhrmalm C, Bondeson K, Bergqvist A, Cox RJ, Tenson T, Merits A, Kainov DE. Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010⁻2018. Viruses. 2019 Mar 1;11(3). pii: E207. doi: 10.3390/v1103020. https://www.mdpi.com/1999-4915/11/3/207
Trieu MC, Zhou F, Lartey SL, Sridhar S, Mjaaland S, Cox RJ. Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. NPJ Vaccines. 2018;3:37; https://pubmed.ncbi.nlm.nih.gov/30131880/
Tete SM, Jul-Larsen A, Rostami S, et al. Cox RJ. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. 2018;36(16):2213-2219; https://pubmed.ncbi.nlm.nih.gov/29548607/
Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25(3):527-534; https://pubmed.ncbi.nlm.nih.gov/29205701/
Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother. 2018;14(3):571-578; https://pubmed.ncbi.nlm.nih.gov/28933664/
Ianevski A, Zusinaite E, Kuivanen S, et al. Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Res. 2018;154:174-182; https://pubmed.ncbi.nlm.nih.gov/29698664/
Brokstad KA, Fredriksen M, Zhou F, et al. Cox RJ. T follicular-like helper cells in the peripheral blood of patients with primary Sjogren's syndrome. Scand J Immunol. 2018:e12679; https://pubmed.ncbi.nlm.nih.gov/29882349/
Mohn KG-I, Zhou F. Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines. 2018; 6(2):32. https://doi.org/10.3390/vaccines6020032. https://www.mdpi.com/2076-393X/6/2/32
2018
2017
Trieu MC, Zhou F, Lartey S, et al. Cox RJ Long-term Maintenance of the Influenza-Specific Cross-Reactive Memory CD4+ T-Cell Responses Following Repeated Annual Influenza Vaccination. J Infect Dis. 2017;215(5):740-749; https://pubmed.ncbi.nlm.nih.gov/28007925/
Savic M, Dembinski JL, Laake I, et al. Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy. PLoS One. 2017;12(11):e0188055; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690673/
Mohn KGI, Zhou F, Brokstad KA, Sridhar S, Cox RJ. Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination. J Infect Dis. 2017;215(10):1527-1535; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461427/
Manenti A, Tete SM, Mohn KG, et al. Cox RJ. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. 2017;35(1):191-198; https://pubmed.ncbi.nlm.nih.gov/27789145/
Jacobsen H, Rajendran M, Choi A, et al. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model. 2017;8(5); https://pubmed.ncbi.nlm.nih.gov/28928215/
Islam S, Mohn KG, Krammer F, et al. Cox RJ Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. 2017;35(42):5666-5673; https://pubmed.ncbi.nlm.nih.gov/28899626/
Ebensen T, Debarry J, Pedersen GK, et al. Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. Front Immunol. 2017;8:1223; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624999/
Dembinski JL, Mihret A, Yimer SA, et al. High Prevalence of Humoral and Cellular Immunity to Influenza Viruses in Preschool Children Living in Addis Ababa, Ethiopia. Open Forum Infect Dis. 2017;4(1):ofx026; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414001/
Andersen TK, Zhou F, Cox RJ, Bogen B, Grodeland G. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza. J Virol. 2017;91(23); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686743/
2017
Voltersvik P, Aqrawi LA, Dudman S, Hungnes O; Norwegian Lung Pathology Group, Bostad L, Brokstad KA, Cox RJ. Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. Influenza Other Respir Viruses. 2016 Nov;10(6):525-531; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059952/
Mohn KG, Brokstad KA, Pathirana RD, Bredholt G, Jul-Larsen Å, Trieu MC, Lartey SL, Montomoli E, Tøndel C, Aarstad HJ, Cox RJ. Live Attenuated Influenza Vaccine in Children Induces B-Cell Responses in Tonsils. J Infect Dis. 2016 Sep 1;214(5):722-31. doi: 10.1093/infdis/jiw230. Epub 2016 May 30. Erratum in: J Infect Dis. 2016 Oct 3; https://pubmed.ncbi.nlm.nih.gov/27247344/
Héquet D, Pascual M, Lartey S, Pathirana RD, Bredholt G, Hoschler K, Hullin R, Meylan P, Cox RJ, Manuel O. Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies. Vaccine. 2016 Jun 30;34(31):3576-83; https://pubmed.ncbi.nlm.nih.gov/27219339/
Eagan TM, Hardie JA, Jul-Larsen Å, Grydeland TB, Bakke PS, Cox RJ. Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. Respir Med. 2016 Jun;115:53-9; https://pubmed.ncbi.nlm.nih.gov/27215504/
Tete SM, Krammer F, Lartey S, Bredholt G, Wood J, Skrede S, Cox RJ. Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination. NPJ Vaccines. 2016;1. pii: 16001; https://www.nature.com/articles/npjvaccines20161
Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Al Mamun A, Anovadiya AP, Araújo WN, Azziz-Baumgartner E, Báez C, Bantar C, Barhoush MM, Bassetti M, Beovic B, Bingisser R, Bonmarin I, Borja-Aburto VH, Cao B, Carratala J, Cuezzo MR, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Fraser J, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hoffmann M, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Khandaker G, Knight M, Kusznierz G, Kuzman I, Kwan AM, Lahlou Amine I, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Manabe T, Mayo-Montero E, McGeer A, Memish ZA, Metan G, Mikić D, Mohn KG, Moradi A, Nymadawa P, Ozbay B, Ozkan M, Parekh D, Paul M, Poeppl W, Polack FP, Rath BA, Rodríguez AH, Siqueira MM, Skręt-Magierło J, Talarek E, Tang JW, Torres A, Törün SH, Tran D, Uyeki TM, van Zwol A, Vaudry W, Velyvyte D, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses. 2016 May;10(3):192-204; https://pubmed.ncbi.nlm.nih.gov/26602067/
Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S. Epitope specific T-cell responses against influenza A in a healthy population. Immunology. 2016 Feb;147(2):165-77; https://pubmed.ncbi.nlm.nih.gov/26489873/
2016
Koch AM, Nilsen RM, Eriksen HM, Cox RJ, Harthug S. Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrob Resist Infect Control. 2015 Dec 29;4:57; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696323/
Mohn KG, Cox RJ, Tunheim G, Berdal JE, Hauge AG, Jul-Larsen Å; Norwegian Pandemic Group, Peters B, Oftung F, Jonassen CM, Mjaaland S. Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway. PLoS One. 2015 Nov 25;10(11):e0143281; https://pubmed.ncbi.nlm.nih.gov/26606759/
Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines.Vaccines (Basel). 2015 Apr 24;3(2):373-89; https://pubmed.ncbi.nlm.nih.gov/26343192/
Panapasa JA, Cox RJ, Mohn KG, Aqrawi LA, Brokstad KA. The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine. Hum Vaccin Immunother. 2015;11(7):1663-72; https://pubmed.ncbi.nlm.nih.gov/26148331/
Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets. PLoS One. 2015 Jul 6;10(7):e0131652; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493055/
Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, Cox RJ. Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 2015 Aug 7;33(33):4146-54; https://pubmed.ncbi.nlm.nih.gov/26057137/
Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum Vaccin Immunother. 2015;11(7):1654-62; https://pubmed.ncbi.nlm.nih.gov/26009966/
Trombetta CM, Perini D, Vitale L, Cox RJ, Stanzani V, Piccirella S, Montomoli E. J. Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses. Immunol Methods. 2015 Jul;422:95-101; https://pubmed.ncbi.nlm.nih.gov/25910832/
Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio. 2015 Mar 10;6(2):e02556; https://pubmed.ncbi.nlm.nih.gov/25759506/
Trondsen M, Aqrawi LA, Zhou F, Pedersen G, Trieu MC, Zhou P, Cox RJ. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice. Scand J Immunol. 2015 May;81(5):305-17; https://pubmed.ncbi.nlm.nih.gov/25737202/
2015
Leonardi-Bee J, Venkatesan S, Muthuri SG, Nguyen-Van-Tam JS, Myles PR; PRIDE research consortium. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014 Jul;2(7):e10-2. doi: 10.1016/S2213-2600(14)70137-7; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(14)70127-4/fulltext
Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ Krammer F. Induction of broadly-reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. Journal of Virology. 2014 Nov;88(22):13260-8. https://pubmed.ncbi.nlm.nih.gov/25210189/
Mart GP, Mohn KG, Cox RJ, Brokstad KA. The influence of tonsillectomy on total serum antibody levels. Scand J Immunol. 2014 Nov;80(5):377-9. https://pubmed.ncbi.nlm.nih.gov/25039393/
Skrede S, Steinsland H, Sommerfelt H, Aase A, Brandtzaeg P, Langeland N, Cox RJ, Sævik M, Wallevik M, Skutlaberg DH, Tellevik MG, Sack DA, Nataro JP, Guttormsen AB. Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward. BMC Infectious Diseases. 2014; Sep 4;14:482. https://pubmed.ncbi.nlm.nih.gov/25190096/
Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD; Convalescent Plasma Study Group, Nguyen-Van-Tam JS, Beck CR. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014 Jul 16. pii: jiu396. https://pubmed.ncbi.nlm.nih.gov/25030060/
Krammer F, Jul-Larsen Å, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clinical and Vaccine Immunology. 2014 Jun 18. pii: CVI.00272-14; https://pubmed.ncbi.nlm.nih.gov/24943383/
Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, Leon de Waal L, Veldhuis Kroeze EJB, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus ADME, Knight A, Oxford JS, Lapini G, Cox RJ, Lambkin-William R. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against Highly Pathogenic Influenza intranasal and intratracheal challenge. PLOSone. 2014;9(5):e93761. https://pubmed.ncbi.nlm.nih.gov/24850536/
Pedersen G, Hoschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralising antibody response after H5N1 vaccination. Vaccine. 2014, ul 31;32(35):4550-7. https://pubmed.ncbi.nlm.nih.gov/24950357/
Muthuri S, Venkatesan S, Myles P, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in hospitalized A(H1N1)pdm09 influenza patients. Lancet Respiratory Medicine. 2014; 2 (5):395-404; https://pubmed.ncbi.nlm.nih.gov/24815805/
Krammer F, Albrecht RA, Tan G, Hai R, Margine I, Schmolke M, Runstadler J, Wilson P, Cox RJ, Treanor JJ, García-Sastre A, Palese P. Divergent H7 immunogens offer protection from H7N9 challenge. Journal of Virology. 2014;88(8):3976-85; https://pubmed.ncbi.nlm.nih.gov/24453375/
Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients; an explorative study. Multiple Sclerosis Journal. 2014 20: 1074-80. https://pubmed.ncbi.nlm.nih.gov/24436455/
Krammer F, Cox RJ. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Review of Vaccines. 2013 Dec;12(12):1369-72; https://pubmed.ncbi.nlm.nih.gov/24160815/
Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen A, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses. 2013 Nov;7(6):1181-93; https://pubmed.ncbi.nlm.nih.gov/23170900/
Jul-Larsen Å, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ. The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Human Vaccines & Immunotherapeutics. 2012 1;8(5). https://pubmed.ncbi.nlm.nih.gov/22634440/
Pedersen GK, Cox RJ. The Mucosal Vaccine Quandary: Intranasal Versus Sublingual Immunisation Against Influenza. Human Vaccines and Immunotherapeutics. 2012 1;8(5). https://pubmed.ncbi.nlm.nih.gov/22495121/
Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhun A, Montomoli E, Gill I, Cox RJ. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses. 2012;6(2):90-100. https://pubmed.ncbi.nlm.nih.gov/21749672/
Simonsen KA, Hunskaar S, Wensaas KA, Rortveit S, Cox R, Njolstad G, et al.Influenza-like illness in general practice in Norway: clinical course and attitudes towards vaccination and preventive measures during the 2009 pandemic. Fam Pract. 2012;29(2):139-46. https://pubmed.ncbi.nlm.nih.gov/21896504/
Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzman CA, et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One. 2011;6(11):e26973. https://pubmed.ncbi.nlm.nih.gov/22069479/
Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses. 2011 Nov;5(6):426-37. https://pubmed.ncbi.nlm.nih.gov/21668670/
Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol. 2011 Aug;74(2):210-8. https://pubmed.ncbi.nlm.nih.gov/21438900/
Madhun AS, Haaheim LR, Nostbakken JK, Ebensen T, Chichester J, Yusibov V, et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine. 2011 Jul 12;29(31):4973-82. https://pubmed.ncbi.nlm.nih.gov/21600260/
Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine. 2011 Oct 19;29(45):8049-59. https://pubmed.ncbi.nlm.nih.gov/21864624/
Haaheim LR, Katz JM. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. Influenza Other Respi Viruses. 2011 Jul;5(4):288-95. https://pubmed.ncbi.nlm.nih.gov/21651740/
Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nostbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 2010 Dec 16;29(2):266-73. https://pubmed.ncbi.nlm.nih.gov/21034828/
2010-2014
Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 2009 Dec 9;27(52):7367-76. https://pubmed.ncbi.nlm.nih.gov/19781678/
Cox RJ, Major D, Hauge S, Madhun AS, Brokstad KA, Kuhne M, Smith J, Vogel FR, Zambon M, Haaheim LR, Wood J. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respi Viruses. 2009 May;3(3):107-17. https://pubmed.ncbi.nlm.nih.gov/19453487/
Hovden AO, Brokstad KA, Major D, Wood J, Haaheim LR, Cox RJ. A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice. Influenza Other Respi Viruses. 2009 Jan;3(1):21-8. https://pubmed.ncbi.nlm.nih.gov/19453438/
Hauge S, Madhun AS, Major D, Brokstad KA, Vogel FR, Zambon M, Wood J, Haaheim LR, Cox RJ. The immunogenicity of a cell-derived H7N1 split influenza virion vaccine in mice. Scand J Immunol. 2009 Jun;69(6):576-8. https://pubmed.ncbi.nlm.nih.gov/19439020/
Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009 Mar 18;27(13):1889-97. https://pubmed.ncbi.nlm.nih.gov/19368768/
Hovden AO, Cox RJ, Haaheim LR. Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(3):229-40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695195/
Eriksson JC, Cox RJ, Szyszko E, Davidsson A, Brokstad KA. Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respi Viruses. 2007 Jul;1(4):139-46. https://pubmed.ncbi.nlm.nih.gov/19432630/
Hauge S, Madhun A, Cox RJ, Haaheim LR. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol. 2007 Aug;14(8):978-83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2044485/
Hauge S, Madhun AS, Cox RJ, Brokstad KA, Haaheim LR. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scand J Immunol. 2007 Jan;65(1):14-21. https://pubmed.ncbi.nlm.nih.gov/17212762/
Cox RJ, Brokstad KA, Haaheim LR. Pandemic influenza vaccine development: time is of the essence. Expert Rev Vaccines. 2006 Oct;5(5):603-6. https://pubmed.ncbi.nlm.nih.gov/17181432/
Szyszko E, Brokstad K, Cox RJ, Hovden AO, Madhun A, Haaheim LR. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol. 2006 Nov;64(5):467-75. https://pubmed.ncbi.nlm.nih.gov/17032238/
Cox RJ, Haaheim LR, Ericsson JC, Madhun AS, Brokstad KA. The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man. Vaccine. 2006 Nov 10;24(44-46):6577-80. https://pubmed.ncbi.nlm.nih.gov/16842889/
Cox RJ, Hovden AO, Brokstad KA, Szyszko E, Madhun AS, Haaheim LR. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 2006 Nov 10;24(44-46):6585-7. https://www.ncbi.nlm.nih.gov/pubmed/16839650
Hovden AO, Cox RJ, Madhun A, Haaheim LR. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand J Immunol. 2005 Oct;62(4):342-52. Erratum in: Scand J Immunol. 2005 Oct;62(4):420. https://pubmed.ncbi.nlm.nih.gov/16253121/
Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005 Jul;62(1):36-44. https://pubmed.ncbi.nlm.nih.gov/16092921/
Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004 Jan;59(1):1-15. https://pubmed.ncbi.nlm.nih.gov/14723616/
Brokstad KA, Eriksson JC, Cox RJ, Tynning T, Olofsson J, Jonsson R, Davidsson A. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis. 2002 Apr 1;185(7):878-84. https://pubmed.ncbi.nlm.nih.gov/11920311/
Cox RJ, Mykkeltvedt E, Robertson J, Haaheim LR. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scand J Immunol. 2002 Jan;55(1):14-23. https://pubmed.ncbi.nlm.nih.gov/11841688/
Cox RJ, Mykkeltvedt E, Sjursen H, Haaheim LR. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 2001 Sep 14;19(32):4743-9. https://pubmed.ncbi.nlm.nih.gov/11535325/
Brokstad KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol. 2001 Jul-Aug;54(1-2):243-7. https://pubmed.ncbi.nlm.nih.gov/11439173/
2000-2009
El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999 Oct;180(4):1356-60. https://pubmed.ncbi.nlm.nih.gov/10479172/
el-Madhun AS, Cox RJ, Søreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis. 1998 Oct;178(4):933-9. https://pubmed.ncbi.nlm.nih.gov/9806018/
el-Madhun AS, Cox RJ, Seime A, Søvik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine. 1998 Jan-Feb;16(2-3):156-60. https://pubmed.ncbi.nlm.nih.gov/9607024/
Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine. 1995 Nov;13(16):1522-8. https://pubmed.ncbi.nlm.nih.gov/8578836/
Brokstad KA, Cox RJ, Oxford JS, Haaheim LR. IgA, IgA subclasses, and secretory component levels in oral fluid collected from subjects after parental influenza vaccination. J Infect Dis. 1995 Apr;171(4):1072-4. https://pubmed.ncbi.nlm.nih.gov/7706797/
Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis. 1995 Jan;171(1):198-203. https://pubmed.ncbi.nlm.nih.gov/7798664/
Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine. 1994 Aug;12(11):993-9. https://pubmed.ncbi.nlm.nih.gov/7975853/
Zuckerman MA, Cox RJ, Oxford JS. Attenuation of virulence in influenza B viral infection of volunteers. J Infect. 1994 Jan;28(1):41-8. https://pubmed.ncbi.nlm.nih.gov/8163832/
Zuckerman M, Cox R, Taylor J, Wood J, Haaheim L, Oxford J. Rapid immune response to influenza vaccination. Lancet. 1993 Oct 30;342(8879):1113. No abstract available. https://pubmed.ncbi.nlm.nih.gov/8105331/
Haaheim LR, Jonsson R. Rapid quality evaluation of hybridomas using ELISPOT and cell-ELISA techniques. Immunol Lett. 1992 Oct-Nov;34(2):135-42. https://pubmed.ncbi.nlm.nih.gov/1487302/
Haaheim LR, Maskell JP, Mascagni P, Coates AR. Fine molecular specificity of linear and assembled antibody binding sites in HIV-1 p24. Scand J Immunol. 1991 Sep;34(3):341-50. https://pubmed.ncbi.nlm.nih.gov/1715604/
Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim LL, Holme I. Benefit of a stroke unit: a randomized controlled trial. Stroke. 1991 Aug;22(8):1026-31. https://pubmed.ncbi.nlm.nih.gov/1866749/
Haaheim LR, Grønning M, Nyland H. Antibodies in sera from Norwegian multiple sclerosis patients and the general population reacting with HTLV-1. A pilot study. APMIS. 1989 Sep;97(9):767-73. https://pubmed.ncbi.nlm.nih.gov/2571350/
Johne B, Jarp J, Haaheim LR. Staphylococcus aureus exopolysaccharide in vivo demonstrated by immunomagnetic separation and electron microscopy. J Clin Microbiol. 1989 Jul;27(7):1631-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC267628/
Wergeland HI, Haaheim LR, Natås OB, Wesenberg F, Oeding P. Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections. J Clin Microbiol. 1989 Jun;27(6):1286-91. https://pubmed.ncbi.nlm.nih.gov/2473994/
Haaheim LR, Kleppe G, Sutherland IW. Monoclonal antibodies reacting with the exopolysaccharide xanthan from Xanthomonas campestris. J Gen Microbiol. 1989 Mar;135(3):605-12. https://pubmed.ncbi.nlm.nih.gov/2621443/
Wergeland HI, Asbakk KB, Haaheim LR. Monoclonal antibodies evoked by the free oligopeptide (Gly)5 reacting specifically with peptidoglycan from staphylococci. J Immunol Methods. 1987 Nov 23;104(1-2):57-63. https://pubmed.ncbi.nlm.nih.gov/3680962/
Aasjord P, Nyland H, Haaheim LR. Intrathecal synthesis of antibodies to staphylococcal antigens in multiple sclerosis patients. Acta Pathol Microbiol Immunol Scand C. 1986 Jun;94(3):97-103. https://pubmed.ncbi.nlm.nih.gov/3751587/
Aasjord P, Haaheim LR. Antibodies to lipoteichoic acid from Staphylococcus aureus. Specificity of murine monoclonal and human antibodies. Acta Pathol Microbiol Immunol Scand C. 1985 Dec;93(6):245-50. https://pubmed.ncbi.nlm.nih.gov/2424261/
Haaheim LR, Lund H. Monoclonal antibodies to the h1 agglutinogen from Staphylococcus aureus 17A. Serological testing with type strains. Acta Pathol Microbiol Immunol Scand B. 1984 Dec;92(6):325-30. https://pubmed.ncbi.nlm.nih.gov/6532111/
Matre R, Haaheim LR, Tönder O. A monoclonal antibody inhibiting human placental Fc gamma-receptor activity. Int Arch Allergy Appl Immunol. 1984;75(3):227-9. https://pubmed.ncbi.nlm.nih.gov/6384062/
Oxford JS, Haaheim LR, Slepushkin A, Werner J, Kuwert E, Schild GC. Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection. J0 Hyg (Lond). 1981 Feb;86(1):17-26. https://pubmed.ncbi.nlm.nih.gov/7462596/
Haaheim LR. Haemagglutination-inhibition antibodies in human sera to an antigenic mutant of influenza A/Texas/1/77 (H3N2) virus obtained in vitro. Acta Pathol Microbiol Scand B. 1980 Dec;88(6):351-3. https://pubmed.ncbi.nlm.nih.gov/6164249/
Haaheim LR, Schild GC. Antibodies to the strain-specific and cross-reactive determinants of the haemagglutinin of influenza H3N2 viruses. Antiviral activities of the antibodies in biological systems. Acta Pathol Microbiol Scand B. 1980 Dec;88(6):335-40. https://pubmed.ncbi.nlm.nih.gov/6164247/
Haaheim LR. Surveillance of the antibody status to current influenza strains in the Norwegian population. 2: Antibodies to the A/USSR/90/77 (H1N1) virus in various age groups after the second epidemic wave. NIPH Ann. 1980 May;3(1):49-56. https://pubmed.ncbi.nlm.nih.gov/7454125/
Haaheim LR. Surveillance of the antibody status to current influenza strains in the Norwegian population. 1: Method of serum sampling and evaluation of the A/USSR/77 (H1N1) impact in various age groups in 1978. NIPH Ann. 1979 Dec;2(2):45-54. https://pubmed.ncbi.nlm.nih.gov/548838/
Haaheim LR, Schild GC. Antibodies to the strain-specific and cross-reactive determinants of the haemagglutinin of influenza H3N2 viruses. 1. Preparation of antibodies and in vitro studies. Acta Pathol Microbiol Scand B. 1979 Oct;87(5):291-9. https://pubmed.ncbi.nlm.nih.gov/93399/
Haaheim LR. Single-radial-complement-fixation: a new immunodiffusion technique. Assay of the antibody response to the type-specific antigens of influenza virus in post-infection human sera. Bull World Health Organ. 1978;56(1):111-6. https://pubmed.ncbi.nlm.nih.gov/96950/
Haaheim LR. Reactivity of rabbit IgG-fragments in single-radial-immunodiffusion. Acta Pathol Microbiol Scand B. 1976 Jun;84(3):159-61. https://pubmed.ncbi.nlm.nih.gov/826108/
Haaheim LR, Schild GC. Antigenic variants of influenza A virus obtained in vitro. Bull World Health Organ. 1976;53(4):305-11. https://pubmed.ncbi.nlm.nih.gov/62624/
English